Ignite Creation Date:
2024-05-05 @ 4:50 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00320632
Status:
COMPLETED
Last Update Posted:
2015-08-19
First Post:
2006-04-28
Brief Title:
Desipramine for Improving Cellular Signaling and Decreasing Symptoms of Major Depression
Sponsor:
Harvard Medical School HMS and HSDM
Organization:
Harvard Medical School HMS and HSDM
Study Overview
Official Title:
Psychopharmacology of Biogenic Amines in Depression
Status:
COMPLETED
Status Verified Date:
2015-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will determine the effectiveness of desipramine in improving cellular signaling and thereby decreasing symptoms of depression in people with major depressive disorder MDD
Detailed Description:
MDD is a serious mental illness that can interfere with a persons ability to eat sleep work and enjoy activities that were once pleasurable It is characterized by several symptoms including as the following persistent sad anxious or empty mood feelings of hopelessness or pessimism and feelings of guilt worthlessness or helplessness The receptor-G protein-adenylate cyclase enzyme complex AC enzyme complex is a major cell signaling system in the brain blood and other tissues in the body Changes in this signaling system among blood cells have been observed in people with major depressive disorder Research has shown that treatment with the benzodiazepine alprazolam corrects the signaling problem and thereby improves symptoms of MDD This study will determine whether impairments in the AC enzyme complex exist among depressed individuals This study will also evaluate the effectiveness of desipramine an antidepressant in improving blood cell signaling and thereby decreasing symptoms of depression in people with major depressive disorder
Both healthy and depressed participants will be recruited for this study All depressed participants in this study will first be assessed for depression severity using the Hamilton Depression Rating Scale If eligible for the study participants will be examined to determine AC enzyme complex functioning in both platelets and mononuclear leukocytes A cohort of the depressed participants will be treated with desipramine They will be examined to determine the drugs effect on AC enzyme complex functioning as well as its effect on MDD symptoms at Weeks 1 4 and 6
Both healthy and depressed participants will be recruited for this study All depressed participants in this study will first be assessed for depression severity using the Hamilton Depression Rating Scale If eligible for the study participants will be examined to determine AC enzyme complex functioning in both platelets and mononuclear leukocytes A cohort of the depressed participants will be treated with desipramine They will be examined to determine the drugs effect on AC enzyme complex functioning as well as its effect on MDD symptoms at Weeks 1 4 and 6
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01MH015413 | NIH | None | httpsreporternihgovquickSearchR01MH015413 |